Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase >> VEGFR

VEGFR

VEGFR are receptors for vascular endothelial growth factor and belong to receptor tyrosine kinases.

Products for  VEGFR

  1. Cat.No. Product Name Information
  2. GC13944 (5Z)-7-Oxozeaenol

    FR148083,L-783,279,LL-Z 1640-2

    TAK1 mitogen-activated protein kinase kinase kinase (MAPKKK) inhibitor

     (5Z)-7-Oxozeaenol Chemical Structure
  3. GC17800 (E)-FeCP-oxindole VEGFR-2 inhibitor (E)-FeCP-oxindole Chemical Structure
  4. GC73527 (S)-SAR131675 (S)-SAR131675 is the S-enantiomer of SAR131675 , a potent and selective VEGFR3 inhibitor and a click chemistry reagent. (S)-SAR131675 Chemical Structure
  5. GC13344 (Z)-FeCP-oxindole VEGFR-2 inhibitor (Z)-FeCP-oxindole Chemical Structure
  6. GC62291 (Z)-Orantinib

    (Z)-SU6668; (Z)-TSU-68

     (Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 ?M, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors. (Z)-Orantinib Chemical Structure
  7. GC33087 2,4-Pyrimidinediamine with linker

    VEGFR-2-IN-5

     2,4-Pyrimidinediamine with linker is a VEGFR2 inhibitor extracted from patent WO2013055780A1, Page 69. 2,4-Pyrimidinediamine with linker Chemical Structure
  8. GC25017 4,4'-Bis(4-aminophenoxy)biphenyl 4,4'-Bis(4-aminophenoxy)biphenyl is a monomer for polyimide production. 4,4'-Bis(4-aminophenoxy)biphenyl Chemical Structure
  9. GC63805 4SC-203 4SC-203 is a potent multikinase inhibitor with potential antineoplastic activity. 4SC-203 selectively FLT3/STK1, FLT3 mutated forms, and VEGFRs. 4SC-203 Chemical Structure
  10. GC68568 5α-Hydroxycostic acid

    5α-Hydroxycostic acid is a diterpenoid extracted from the herb Laggera alata. It inhibits angiogenesis and suppresses breast cancer cell migration by regulating the VEGF/VEGFR2 and Ang2/Tie2 pathways.

     5α-Hydroxycostic acid Chemical Structure
  11. GC10938 AAL-993

    VEGFR Tyrosine Kinase Inhibitor VI,ZK 260253

     VEGF receptors inhibitor AAL-993 Chemical Structure
  12. GC30242 Acrizanib

    LHA510

     Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-VEGFR-2. Acrizanib Chemical Structure
  13. GC15801 ACTB-1003

    ACTB-1003

     ACTB-1003 (ACTB-1003) is an oral kinase inhibitor with IC50s of 6, 2 and 4 nM for FGFR1, VEGFR2 and Tie-2. ACTB-1003 Chemical Structure
  14. GC68628 Aflibercept

    VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1

     Aflibercept is a high-affinity soluble decoy vascular endothelial growth factor (VEGF) receptor and a potent angiogenesis inhibitor that binds vascular endothelial growth factor and placental growth factor (PlGF) with extremely high affinity. Preclinical studies have shown that Aflibercept has potent antitumor and antiangiogenic activities against a variety of tumors, including melanoma and solid tumors. Aflibercept Chemical Structure
  15. GC35263 AG-13958 AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD). AG-13958 Chemical Structure
  16. GC16604 Altiratinib

    DCC-2701

     c-MET/TIE-2/VEGFR inhibitor Altiratinib Chemical Structure
  17. GC45677 Anlotinib (hydrochloride) A neuropeptide with diverse biological activities Anlotinib (hydrochloride) Chemical Structure
  18. GC14292 Apatinib Mesylate

    YN968D1

     Apatinib Mesylate blocks the downstream signal transduction of VEGF pathway to inhibit neovascularization. Apatinib Mesylate Chemical Structure
  19. GC10914 AST 487

    NVP-AST 487

     A multi-kinase inhibitor AST 487 Chemical Structure
  20. GC12216 Axitinib (AG 013736)

    AG 013736

     Axitinib (AG 013736) is an orally active specific vascular endothelial growth factor receptor (VEGFR) inhibitor that targets VEGFR-1, VEGFR-2, and VEGFR-3 with IC50 values of 0.1nM, 0.2nM, and 0.1-0.3nM, respectively. Axitinib (AG 013736) Chemical Structure
  21. GC62185 Axitinib-d3

    AG-013736-d3

     Axitinib-d3 (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively. Axitinib-d3 Chemical Structure
  22. GC17959 AZD2932 inhibitor of VEGFR-2, PDGFRβ, Flt-3, and c-Kit AZD2932 Chemical Structure
  23. GC11726 BAW2881 (NVP-BAW2881)

    NVP-BAW 2881

     BAW2881 (NVP-BAW2881) (BAW2881) is a potent and selective VEGFR2 inhibitor with an IC50 of 4 nM. BAW2881 (NVP-BAW2881) Chemical Structure
  24. GC45830 BAY-1125976 An allosteric inhibitor of Akt1/2 BAY-1125976 Chemical Structure
  25. GC34216 Bevacizumab (Anti-Human VEGF, Humanized Antibody) Bevacizumab is a humanized monoclonal antibody against VEGF. Bevacizumab (Anti-Human VEGF, Humanized Antibody) Chemical Structure
  26. GC15340 BFH772 VEGFR2 inhibitor BFH772 Chemical Structure
  27. GC46924 BIBF 1120-13C-d3

    Nintedanib-13C-d3

     A neuropeptide with diverse biological activities BIBF 1120-13C-d3 Chemical Structure
  28. GC35516 BIBF 1202 BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC50 of 62 nM. BIBF 1202 Chemical Structure
  29. GC50330 BMS 605541 Potent VEGFR-2 inhibitor BMS 605541 Chemical Structure
  30. GC13873 BMS-690514 BMS-690514 Chemical Structure
  31. GC13833 BMS-794833 Met/VEGFR-2 inhibitor,potent and ATP-competitive BMS-794833 Chemical Structure
  32. GC11692 Brivanib (BMS-540215)

    BMS 540215

     Brivanib (BMS-540215) (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β. Brivanib (BMS-540215) Chemical Structure
  33. GC14238 Brivanib Alaninate (BMS-582664)

    BMS 582664

     Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ. Brivanib Alaninate (BMS-582664) Chemical Structure
  34. GC74575 Brolucizumab

    DLX1008; ESBA 1008; RTH258

     Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM). Brolucizumab Chemical Structure
  35. GC15779 Cabozantinib (XL184, BMS-907351)

    BMS-907351, Cabozantinib

     Cabozantinib (XL184,BMS-907351) is a novel MET and VEGFR2 inhibitor that simultaneously inhibits metastasis, angiogenesis and tumor growth. Cabozantinib (XL184, BMS-907351) Chemical Structure
  36. GC12531 Cabozantinib malate (XL184) Cabozantinib malate (XL184) (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively. Cabozantinib malate (XL184) Chemical Structure
  37. GC67948 Cabozantinib-d6

    XL184-d6; BMS-907351-d6

     Cabozantinib-d6 Chemical Structure
  38. GC16421 Cediranib (AZD217)

    AZD 2171, ZD 2171

     Cediranib (AZD217) (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively. Cediranib (AZD217) Chemical Structure
  39. GC33004 Cediranib maleate (AZD-2171 maleate) Cediranib maleate (AZD-2171 maleate) (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively. Cediranib maleate (AZD-2171 maleate) Chemical Structure
  40. GC73947 CEP-11981

    ESK981; BOL 303213X

     CEP-11981(ESK981; BOL 303213X) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, VEGFR1-3 and FGFR1, and has potential anti-tumor and anti-angiogenic effects. CEP-11981 Chemical Structure
  41. GC14650 CGP60474 A CDK inhibitor CGP60474 Chemical Structure
  42. GC62145 Chiauranib

    CS2164

     Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects. Chiauranib Chemical Structure
  43. GC32979 Chloropyramine hydrochloride Chloropyramine hydrochloride is a histamine receptor H1 antagonist which can also inhibit the biochemical function of VEGFR-3 and FAK. Chloropyramine hydrochloride Chemical Structure
  44. GC33352 CP-547632 A potent inhibitor of VEGFR2 and bFGF CP-547632 Chemical Structure
  45. GC38575 CP-547632 hydrochloride CP-547632 hydrochloride is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 hydrochloride has antitumor efficacy. CP-547632 hydrochloride Chemical Structure
  46. GC60726 CP-547632 TFA CP-547632 TFA is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy. CP-547632 TFA Chemical Structure
  47. GC12980 CP-673451 PDGFRα/β inhibitor,potent and selective CP-673451 Chemical Structure
  48. GC91419 CYY292 CYY292 is an inhibitor of PDGFRα, PDGFRβ, FGFR1, -2, and -3, (IC50s = 5.35, 4.6, 28, 28, and 78 nM, respectively). CYY292 Chemical Structure
  49. GC17098 DMH4 VEGFR-2 inhibitor DMH4 Chemical Structure
  50. GC13547 Dovitinib (TKI-258, CHIR-258)

    CHIR258, TKI-258

     Dovitinib (TKI-258, CHIR-258) (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib (TKI-258, CHIR-258) has potent antitumor activity. Dovitinib (TKI-258, CHIR-258) Chemical Structure
  51. GC10165 Dovitinib (TKI258) Lactate Dovitinib (TKI258) Lactate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively. Dovitinib (TKI258) Lactate Chemical Structure
  52. GC11372 Dovitinib Dilactic acid FLT3 inhibitor Dovitinib Dilactic acid Chemical Structure
  53. GC12149 E-3810 E-3810 Chemical Structure
  54. GC16183 EG00229

    Nrp1 inhibitor

     EG00229 Chemical Structure
  55. GC16519 ENMD-2076 A multi-kinase inhibitor ENMD-2076 Chemical Structure
  56. GC12145 ENMD-2076 L-(+)-Tartaric acid ENMD-2076 L-(+)-Tartaric acid Chemical Structure
  57. GC64836 Famitinib Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis. Famitinib Chemical Structure
  58. GC72336 Faricimab Faricimab is a bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A). Faricimab Chemical Structure
  59. GC15735 Foretinib (GSK1363089)

    GSK1363089, XL880

     Foretinib (GSK1363089) is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR. Foretinib (GSK1363089) Chemical Structure
  60. GC10355 Fruquintinib(HMPL-013)

    HMPL-013

     Fruquintinib(HMPL-013) (HMPL-013) is a highly potent and selective VEGFR 1/2/3 inhibitor with IC50s of 33, 0.35, and 35 nM, respectively. Fruquintinib(HMPL-013) Chemical Structure
  61. GC17715 Golvatinib (E7050)

    E7050

     Golvatinib (E7050) (E-7050) is a potent dual inhibitor of both c-Met and VEGFR2 kinases with IC50s of 14 and 16 nM, respectively. Golvatinib (E7050) Chemical Structure
  62. GC36203 GW806742X GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X Chemical Structure
  63. GC61454 GW806742X hydrochloride GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC50=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis. GW806742X hydrochloride Chemical Structure
  64. GC32963 hVEGF-IN-1 hVEGF-IN-1, a quinazoline derivative, could specifically bind to the G-rich sequence in the internal ribosome entry site A (IRES-A) and destabilize the G-quadruplex structure. hVEGF-IN-1 binds to the IRES-A (WT) with a Kd of 0.928 μM in SPR experiments. hVEGF-IN-1 could hinder tumor cells migration and repress tumor growth by decreasing VEGF-A protein expression. hVEGF-IN-1 Chemical Structure
  65. GC73902 hVEGF-IN-3 hVEGF-IN-3 (compound 9) is a potent hVEGF inhibitor. hVEGF-IN-3 inhibits HT-29, MCF-7, and HEK-293 cells proliferation with IC50s of 61, 142, and 114 μM. hVEGF-IN-3 Chemical Structure
  66. GC43885 Hypothemycin

    NSC 354462

     A resorcylic acid lactone polyketide Hypothemycin Chemical Structure
  67. GC69252 Icrucumab

    Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1

    Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a humanized monoclonal antibody against VEGFR-1 IgG1. Icrucumab has the potential for use in late-stage solid tumor research.

     Icrucumab Chemical Structure
  68. GC34159 Ilorasertib (ABT-348)

    ABT-348

     Ilorasertib (ABT-348) (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib (ABT-348) also is a potent VEGF, PDGF inhibitor. Ilorasertib (ABT-348) has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Ilorasertib (ABT-348) Chemical Structure
  69. GC38519 Ilorasertib hydrochloride

    ABT-348 hydrochloride

     Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Ilorasertib hydrochloride Chemical Structure
  70. GC74564 Ivonescimab

    AK112

     Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab Chemical Structure
  71. GC18168 JI-101

    CGI1842

    An orally active inhibitor

     JI-101 Chemical Structure
  72. GC32625 KDR-in-4

    KDR-in-4

     KDR-in-4 (KDR-in-4) is a potent kinase insert domain-containing receptor (KDR/VEGFR2) inhibitor with an IC50 of 7 nM. KDR-in-4 Chemical Structure
  73. GC13264 Ki20227

    Ki 20227;Ki-20227

     A c-Fms kinase inhibitor Ki20227 Chemical Structure
  74. GC11666 Ki8751 VEGFR-2 inhibitor,potent and selective Ki8751 Chemical Structure
  75. GC72285 KLTWQELYQLKYKGI KLTWQELYQLKYKGI (QK) is a VEGF mimicking peptide, binds to the VEGF receptors and competes with VEGF. KLTWQELYQLKYKGI Chemical Structure
  76. GC12590 KRN 633 VEGFR inhibitor,ATP-competitive KRN 633 Chemical Structure
  77. GC15454 Lenvatinib (E7080)

    E-7080, ER-203492-00

     E7080, known as lenvatinib, is an oral multitargeted tyrosine kinase inhibitor including VEGF, FGF and SCF receptors that has been shown to improve the survival rate of patients with radioiodine-refractory thyroid cancer.  Lenvatinib (E7080) Chemical Structure
  78. GC36438 Lenvatinib mesylate

    E-7080

     An inhibitor of VEGFR2 and VEGFR3 Lenvatinib mesylate Chemical Structure
  79. GC45754 Lenvatinib-d4

    E7080-d4

     A neuropeptide with diverse biological activities Lenvatinib-d4 Chemical Structure
  80. GC17958 Linifanib (ABT-869)

    Linifanib

     Linifanib (ABT-869) (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (ABT-869) shows prominent antitumor activity. Linifanib (ABT-869) has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib (ABT-869) is a specific miR-10b inhibitor that blocks miR-10b biogenesis. Linifanib (ABT-869) Chemical Structure
  81. GC13848 LY2784544

    Gandotinib

     Potent inhibitor of JAK2 LY2784544 Chemical Structure
  82. GC16483 MAZ51 MAZ51 is a selective vascular endothelial growth factor receptor 3 (VEGFR-3; FLT4) tyrosine kinase inhibitor. MAZ51 Chemical Structure
  83. GC74096 MET kinase-IN-4 MET kinase-IN-4 is an orally active Met kinase inhibitor. MET kinase-IN-4 Chemical Structure
  84. GC13598 MGCD-265 MGCD-265 is a potent and oral active inhibitor of c-Met and VEGFR2 tyrosine kinases, with IC50s of 29 nM and 10 nM, respectively. MGCD-265 has significant antitumor activity. MGCD-265 Chemical Structure
  85. GC13012 Motesanib Motesanib Chemical Structure
  86. GC11336 Motesanib Diphosphate (AMG-706)

    Motesanib

     Motesanib Diphosphate (AMG-706) (AMG 706 Diphosphate) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret. Motesanib Diphosphate (AMG-706) Chemical Structure
  87. GC73264 Multi-target kinase inhibitor 2 Multi-target kinase inhibitor 2 (compound 5K) is a multi-targeted kinase inhibitor, and exhibits activity against EGFR, Her2, VEGFR2, and CDK2 enzymes, with IC50 values ranging from 40 to 204 nM. Multi-target kinase inhibitor 2 Chemical Structure
  88. GC49686 N-desmethyl Regorafenib N-oxide An active metabolite of regorafenib N-desmethyl Regorafenib N-oxide Chemical Structure
  89. GC18211 Ningetinib A multi-kinase inhibitor Ningetinib Chemical Structure
  90. GC36744 Ningetinib Tosylate Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively. Ningetinib Tosylate Chemical Structure
  91. GC36745 Nintedanib esylate

    Nintedanib

     Nintedanib esylate, as a kinase inhibitor, used for the treatment of non-small cell lung cancer suffered from first-pass metabolism which resulted in low oral bioavailability (~ 4.7%). Nintedanib esylate Chemical Structure
  92. GC34126 NVP-ACC789 (ACC-789) NVP-ACC789 (ACC-789) is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC50s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively. NVP-ACC789 (ACC-789) Chemical Structure
  93. GC44474 NVP-AEW541 (hydrochloride) Insulin-like growth factor 1 receptor (IGF-1R) is a receptor tyrosine kinase whose activation leads to angiogenesis as well as cell proliferation, survival, transformation, and metastasis. NVP-AEW541 (hydrochloride) Chemical Structure
  94. GC64950 ODM-203 ODM-203 is an orally active and selective FGFR/VEGFR inhibitor with IC50 values of 6, 11, 16, 5, 9, 26 and 35 nM for FGFR3/1/2 and VEGFR3/2/1/4, respectively. ODM-203 has strong anti-tumour activity and activates immune responses in the tumour microenvironment. ODM-203 Chemical Structure
  95. GC32502 Oglufanide (H-Glu-Trp-OH) Oglufanide (H-Glu-Trp-OH) (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide (H-Glu-Trp-OH) Chemical Structure
  96. GC74587 Olinvacimab

    TTAC-0001

     Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab Chemical Structure
  97. GC14957 OSI-930 Inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck OSI-930 Chemical Structure
  98. GC69662 Parsatuzumab

    Anti-EGFL7; RG 7414

    Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody that binds to EGFL7 as an immune modulator. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, which may inhibit angiogenesis and reduce the inhibition of vascular endothelial growth factor (VEGF).

     Parsatuzumab Chemical Structure
  99. GC16327 Pazopanib (GW-786034)

    GSK-VEG10003, GW786034B

     A multi-kinase inhibitor Pazopanib (GW-786034) Chemical Structure
  100. GC12730 Pazopanib Hydrochloride

    GW786034;Votrient;Armala;GW 786034;GW-786034

     VEGFR/PDGFR/FGFR/c-Kit/ c-Fms inhibitor Pazopanib Hydrochloride Chemical Structure
  101. GC72911 Pazopanib-13C,d3 hydrochloride

    GW786034-13C,d3 hydrochloride

     Pazopanib-13C,d3 (drochloride) is the deuterium and 13C labeled Pazopanib drochloride. Pazopanib-13C,d3 hydrochloride Chemical Structure

Items 1 to 100 of 188 total

per page
  1. 1
  2. 2

Set Descending Direction